FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885048098> ?p ?o ?g. }

• W2885048098 abstract "Adoptive cell therapy (ACT) utilizing tumor-infiltrating lymphocytes (TIL) has been employed for years in hundreds of patients with metastatic melanoma and other solid tumors, demonstrating durable and complete responses, even in heavily pretreated patients. Despite the approvals of checkpoint-directed therapies, metastatic melanoma remains an unmet need due to progression subsequent to administration of checkpoints, as well as due to intolerance. The C-144-01 study will enroll metastatic melanoma patients who progressed on anti-PD-1 and BRAF inhibitors if BRAF mutation positive. This phase II trial utilizes a central GMP facility for the manufacture of LN-144 in either a non-cryopreserved generation-1 (Gen-1), or cryopreserved generation-2 (Gen-2) investigational TIL infusion product. The Gen-2 manufacturing process reduces the time required for manufacture of TIL product to 22 days. The process development of cryopreservation for the final LN-144 infusion product incorporates dramatic improvements in the flexibility of scheduling, distribution and delivery required for commercial use. C-144-01 (NCT02360579) is a global phase 2 multicenter, open-label study evaluating the efficacy and safety of autologous TIL (LN-144) therapy for the treatment of patients with advanced metastatic melanoma. The study consists of three treatment cohorts: 30 patients in Cohort 1 will receive a single dose of Gen-1, non-cryopreserved LN-144; 30 patients in Cohort 2 will receive a single dose of Gen-2, cryopreserved LN-144; and up to 10 eligible patients from either Cohort 1 or Cohort 2 may enter a third cohort (Cohort 3) for re-treatment with a second dose of LN-144. The investigational LN-144 TIL infusion product for all cohorts is prepared at the central GMP facility using lymphocytes that are extracted from a surgically-resected sample of patient tumor. LN-144 infusion is preceded by a non-myeloablative lymphodepletion regimen of cyclophosphamide and fludarabine and followed by IL-2 for up to 6 doses. Patients ≥ 18 years of age must have progressive, unresectable metastatic melanoma (Stage IIIc or Stage IV) following ≥1 line of prior systemic therapy including immune checkpoint inhibitors and BRAF-targeted therapy (if BRAF mutation-positive). A minimum of 2 tumor lesions are required: 1 for resection and TIL manufacture and 1 for assessment of response by RECIST 1.1 criteria. Other major eligibility criteria include: adequate bone marrow, cardiac, liver, pulmonary, and renal function; ECOG PS of 0 or 1. Efficacy is being assessed as a function of ORR, CR rate, DOR, DCR, and PFS per RECIST 1.1 and OS. Assessment of safety data will be descriptive and based on the summarization of TEAEs, SAEs, AEs leading to discontinuation from treatment and the study, vital signs, physical examinations, and clinical laboratory tests. Citation Format: Amod Sarnaik, Brendan Curti, Diwakar Davar, Omid Hamid, Jose Lutzky, Melissa Wilson, Harriet Kluger, Jason Chesney, Kevin Kim, Giao Phan, Sajeve Thomas, Eric Whitman, Bente Larsen, Sam Suzuki, Nancy Samberg, Igor Gorbatchevsky, Maria Fardis, John M. Kirkwood. A phase II, multicenter study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients with metastatic melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT169." @default.
• W2885048098 created "2018-08-22" @default.
• W2885048098 creator A5001175430 @default.
• W2885048098 creator A5006404846 @default.
• W2885048098 creator A5007239425 @default.
• W2885048098 creator A5011707021 @default.
• W2885048098 creator A5028592995 @default.
• W2885048098 creator A5029588412 @default.
• W2885048098 creator A5030169825 @default.
• W2885048098 creator A5033965725 @default.
• W2885048098 creator A5037212641 @default.
• W2885048098 creator A5037624715 @default.
• W2885048098 creator A5039517975 @default.
• W2885048098 creator A5051355971 @default.
• W2885048098 creator A5052543382 @default.
• W2885048098 creator A5065290717 @default.
• W2885048098 creator A5086165685 @default.
• W2885048098 creator A5088471524 @default.
• W2885048098 creator A5088744286 @default.
• W2885048098 creator A5091169382 @default.
• W2885048098 date "2018-07-01" @default.
• W2885048098 modified "2023-10-14" @default.
• W2885048098 title "Abstract CT169: A phase II, multicenter study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients with metastatic melanoma" @default.
• W2885048098 doi "https://doi.org/10.1158/1538-7445.am2018-ct169" @default.
• W2885048098 hasPublicationYear "2018" @default.
• W2885048098 type Work @default.
• W2885048098 sameAs 2885048098 @default.
• W2885048098 citedByCount "0" @default.
• W2885048098 crossrefType "proceedings-article" @default.
• W2885048098 hasAuthorship W2885048098A5001175430 @default.
• W2885048098 hasAuthorship W2885048098A5006404846 @default.
• W2885048098 hasAuthorship W2885048098A5007239425 @default.
• W2885048098 hasAuthorship W2885048098A5011707021 @default.
• W2885048098 hasAuthorship W2885048098A5028592995 @default.
• W2885048098 hasAuthorship W2885048098A5029588412 @default.
• W2885048098 hasAuthorship W2885048098A5030169825 @default.
• W2885048098 hasAuthorship W2885048098A5033965725 @default.
• W2885048098 hasAuthorship W2885048098A5037212641 @default.
• W2885048098 hasAuthorship W2885048098A5037624715 @default.
• W2885048098 hasAuthorship W2885048098A5039517975 @default.
• W2885048098 hasAuthorship W2885048098A5051355971 @default.
• W2885048098 hasAuthorship W2885048098A5052543382 @default.
• W2885048098 hasAuthorship W2885048098A5065290717 @default.
• W2885048098 hasAuthorship W2885048098A5086165685 @default.
• W2885048098 hasAuthorship W2885048098A5088471524 @default.
• W2885048098 hasAuthorship W2885048098A5088744286 @default.
• W2885048098 hasAuthorship W2885048098A5091169382 @default.
• W2885048098 hasConcept C126322002 @default.
• W2885048098 hasConcept C141071460 @default.
• W2885048098 hasConcept C143998085 @default.
• W2885048098 hasConcept C2775832928 @default.
• W2885048098 hasConcept C2777658100 @default.
• W2885048098 hasConcept C2994587330 @default.
• W2885048098 hasConcept C502942594 @default.
• W2885048098 hasConcept C71924100 @default.
• W2885048098 hasConcept C72563966 @default.
• W2885048098 hasConceptScore W2885048098C126322002 @default.
• W2885048098 hasConceptScore W2885048098C141071460 @default.
• W2885048098 hasConceptScore W2885048098C143998085 @default.
• W2885048098 hasConceptScore W2885048098C2775832928 @default.
• W2885048098 hasConceptScore W2885048098C2777658100 @default.
• W2885048098 hasConceptScore W2885048098C2994587330 @default.
• W2885048098 hasConceptScore W2885048098C502942594 @default.
• W2885048098 hasConceptScore W2885048098C71924100 @default.
• W2885048098 hasConceptScore W2885048098C72563966 @default.
• W2885048098 hasLocation W28850480981 @default.
• W2885048098 hasOpenAccess W2885048098 @default.
• W2885048098 hasPrimaryLocation W28850480981 @default.
• W2885048098 hasRelatedWork W2324802203 @default.
• W2885048098 hasRelatedWork W2509207873 @default.
• W2885048098 hasRelatedWork W2603903176 @default.
• W2885048098 hasRelatedWork W2806277324 @default.
• W2885048098 hasRelatedWork W2884196078 @default.
• W2885048098 hasRelatedWork W2885048098 @default.
• W2885048098 hasRelatedWork W2954578306 @default.
• W2885048098 hasRelatedWork W3193367738 @default.
• W2885048098 hasRelatedWork W42605560 @default.
• W2885048098 hasRelatedWork W4289878870 @default.
• W2885048098 isParatext "false" @default.
• W2885048098 isRetracted "false" @default.
• W2885048098 magId "2885048098" @default.
• W2885048098 workType "article" @default.